Thomas Danne, Bertrand Cariou, Phillip Banks, Michael Brandle, Helmut Brath, Edward Franek, Jake A Kushner, Pablo Lapuerta, Darren K McGuire, Anne L Peters, Sangeeta Sawhney, Paul Strumph. Diabetes Care 2018
Times Cited: 52
Times Cited: 52
Anne L Peters, Elizabeth O Buschur, John B Buse, Pejman Cohan, Jamie C Diner, Irl B Hirsch. Diabetes Care 2015
Times Cited: 323
Times Cited: 323
List of shared articles
Times cited
Sodium-Glucose Cotransporter 2 Inhibitors: A Case Study in Translational Research.
Amber L Beitelshees, Bruce R Leslie, Simeon I Taylor. Diabetes 2019
Amber L Beitelshees, Bruce R Leslie, Simeon I Taylor. Diabetes 2019
Strategy for Mitigating DKA Risk in Patients with Type 1 Diabetes on Adjunctive Treatment with SGLT Inhibitors: A STICH Protocol.
Satish K Garg, Anne L Peters, John B Buse, Thomas Danne. Diabetes Technol. Ther. 2018
Satish K Garg, Anne L Peters, John B Buse, Thomas Danne. Diabetes Technol. Ther. 2018
Efficacy and safety of dual SGLT 1/2 inhibitor sotagliflozin in type 1 diabetes: meta-analysis of randomised controlled trials.
Giovanni Musso, Roberto Gambino, Maurizio Cassader, Elena Paschetta. BMJ 2019
Giovanni Musso, Roberto Gambino, Maurizio Cassader, Elena Paschetta. BMJ 2019
Sodium-glucose co-transporter inhibitors as adjunctive treatment to insulin in type 1 diabetes: A review of randomized controlled trials.
Schafer Boeder, Steven V Edelman. Diabetes Obes Metab 2019
Schafer Boeder, Steven V Edelman. Diabetes Obes Metab 2019
Sotagliflozin in Combination With Optimized Insulin Therapy in Adults With Type 1 Diabetes: The North American inTandem1 Study.
John B Buse, Satish K Garg, Julio Rosenstock, Timothy S Bailey, Phillip Banks, Bruce W Bode, Thomas Danne, Jake A Kushner, Wendy S Lane, Pablo Lapuerta,[...]. Diabetes Care 2018
John B Buse, Satish K Garg, Julio Rosenstock, Timothy S Bailey, Phillip Banks, Bruce W Bode, Thomas Danne, Jake A Kushner, Wendy S Lane, Pablo Lapuerta,[...]. Diabetes Care 2018
Dose-dependent glycometabolic effects of sotagliflozin on type 1 diabetes over 12 weeks: The inTandem4 trial.
Claire Baker, Suman Wason, Phillip Banks, Sangeeta Sawhney, Anna Chang, Thomas Danne, Diane Gesty-Palmer, Jake A Kushner, Darren K McGuire, Frank Mikell,[...]. Diabetes Obes Metab 2019
Claire Baker, Suman Wason, Phillip Banks, Sangeeta Sawhney, Anna Chang, Thomas Danne, Diane Gesty-Palmer, Jake A Kushner, Darren K McGuire, Frank Mikell,[...]. Diabetes Obes Metab 2019
Sotagliflozin: a combined SGLT1/SGLT2 inhibitor to treat diabetes.
Marc S Rendell. Expert Rev Endocrinol Metab 2018
Marc S Rendell. Expert Rev Endocrinol Metab 2018
SGLT Inhibitors for Type 1 Diabetes: An Obvious Choice or Too Good to Be True?
Matthew C Riddle, William T Cefalu. Diabetes Care 2018
Matthew C Riddle, William T Cefalu. Diabetes Care 2018
Beyond type 2 diabetes: sodium glucose co-transporter-inhibition in type 1 diabetes.
Torben Biester, Olga Kordonouri, Thomas Danne. Diabetes Obes Metab 2019
Torben Biester, Olga Kordonouri, Thomas Danne. Diabetes Obes Metab 2019
Adjunct Antihyperglycemic Agents in Overweight and Obese Adults With Type 1 Diabetes.
Diana Isaacs, Stephanie Yager, Marcie Parker, Lauren Wolfe, Jennifer Luxenburg, Sanela Lekic. Ann Pharmacother 2019
Diana Isaacs, Stephanie Yager, Marcie Parker, Lauren Wolfe, Jennifer Luxenburg, Sanela Lekic. Ann Pharmacother 2019
SGLT2 inhibitors as adjunctive therapy for type 1 diabetes: balancing benefits and risks.
Simeon I Taylor, Jenny E Blau, Kristina I Rother, Amber L Beitelshees. Lancet Diabetes Endocrinol 2019
Simeon I Taylor, Jenny E Blau, Kristina I Rother, Amber L Beitelshees. Lancet Diabetes Endocrinol 2019
Licogliflozin, a Novel SGLT1 and 2 Inhibitor: Body Weight Effects in a Randomized Trial in Adults with Overweight or Obesity.
Harold E Bays, Plamen Kozlovski, Qing Shao, Pieter Proot, Deborah Keefe. Obesity (Silver Spring) 2020
Harold E Bays, Plamen Kozlovski, Qing Shao, Pieter Proot, Deborah Keefe. Obesity (Silver Spring) 2020